ReviewInsights into imaging2025
Washed up: the end of an era for adrenal incidentaloma CT.
Review in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Histological spectrum of resected adrenal tumors in the 11-20 HU grey zone on unenhanced CT: a retrospective cohort study.Updates in surgery · 2026Article
- Adrenohepatic Adhesion/Fusion Mimicking Hepatic Invasion: Two Cases of Benign Right Adrenal Lesions and a Review of the Literature.Diagnostics (Basel, Switzerland) · 2026Article
- Fat matters: practical imaging approach to microscopic and macroscopic fat in adrenal nodules.Abdominal radiology (New York) · 2026Review
- Outcomes and opportunities: evaluating an unselected cohort of patients with adrenal incidentaloma at a tertiary hospital in New Zealand.Internal medicine journal · 2026Article
- Differentiation of Adrenal Adenomas from Non-Adenomatous Lesions: Diagnostic Value of Unenhanced Spectral CT.Tomography (Ann Arbor, Mich.) · 2026Article
- [Diagnostics and surgery of mild autonomous cortisol secretion (MACS)].Chirurgie (Heidelberg, Germany) · 2026Article
- Evaluation of adrenal incidentalomas: Current approaches, caveats, and unexplored issues.World journal of radiology · 2026Review
- Pitfalls of Adrenal Washout on CT in the Adult Population: A Pictorial Review.Diagnostics (Basel, Switzerland) · 2026Review
- Beyond attenuation: AI for differentiating lipid-poor adrenal adenoma and nodular hyperplasia.European radiology · 2026Article
- Synchronous bone and adrenal extramedullary plasmacytoma: a rare case report and literature review.World journal of surgical oncology · 2025Review
- Adrenal Incidentaloma: From Silent Diagnosis to Clinical Challenge.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For over 20 years, the two key tenets of adrenal incidentaloma (AI) evaluation have been the upper threshold of 10 Hounsfield units (HU) on noncontrast CT (ncCT) to delineate benignity, and the utilisation of adrenal washout CT (AWCT) to evaluate those above this cutoff. In light of growing recent evidence that challenges these two traditional principles, as well as re-evaluation of the data that led to their acceptance, we conclude that neither of these mainstays of adrenal CT remains relevant in modern AI diagnostic workup. With an appropriate definition of an incidentaloma and endocrine assessment for the majority of adrenal lesions, our analysis establishes that the use of AWCT should be ceased in the assessment of AIs, and that a 20 HU attenuation threshold for lesions < 4 cm should replace the traditional 10 HU threshold to exclude malignancy in this patient population. We therefore propose new recommendations for the management of AIs based primarily on CT attenuation and lesion size on ncCT. CRITICAL RELEVANCE STATEMENT: Increasing the CT attenuation threshold to 20 HU for lesions < 4 cm and eliminating washout CT for true adrenal incidentalomas, together with recommendations for endocrine assessment, will significantly decrease the over-investigation of overwhelmingly benign adrenal lesions, whilst confidently excluding malignancy. KEY POINTS: True incidentalomas exclude current or prior extra-adrenal malignancy and clinically suspected adrenal disease. Adrenal washout CT was never proven in the malignancy-sparse true incidentaloma population. Hormonal correlation in parallel with < 20 HU and < 4 cm thresholds of homogeneous lesions on noncontrast CT excludes malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.